Open AccessQuantification of XRCC and DNA-PK proteins in cancer cell lines and human tumors by LC–MS/MS
Author(s) -
Matthew V. Myers,
Stephen E. Maxwell,
Xiaomin Wang
Publication year - 2014
Publication title -
bioanalysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.566
H-Index - 58
eISSN - 1757-6199
pISSN - 1757-6180
DOI - 10.4155/bio.14.121
Subject(s) - hela , microbiology and biotechnology , dna , biology , serine , chemistry , biochemistry , in vitro , phosphorylation
Background: The x-ray repair cross-complementing (XRCC) proteins and a catalytic subunit of nuclear DNA-dependent serine/threonine protein kinase (DNA-PK) play important roles in cancer biology. Understanding the protein expression levels allows us to reconstruct in vivo functionality and to qualify protein biomarkers. Methods & results: XRCC and DNA-PK proteins in human cancer cells and tumor tissues have been identified and quantified by selected peptides using NanoLC and high-resolution mass spectrometry. The stable isotope-labeled full-length protein XRCC4 ([ 13 C 6 , 15 N 4 ]-arginine and [ 13 C 6 , 15 N 2 ]-lysine) uses as the internal standard. Conclusion: The assay range is 0.140–450 fmol (coefficient of variation: 25%) for XRCC4 in bovine serum albumen. The quantitative protein expression levels for XRCC and DNA-PK in HeLa, Ramos and HEK-293 cells and tumor tissues (lung and lymphoma) are reported